Screener
Cytek Biosciences, Inc. CTKB Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Cytek Biosciences, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053496
FAQ
- What is Cytek Biosciences, Inc.'s debt-to-equity?
- Cytek Biosciences, Inc. (CTKB) reported debt-to-equity of 0.1× in Q2 2026.
- How has Cytek Biosciences, Inc.'s debt-to-equity changed year-over-year?
- Cytek Biosciences, Inc.'s debt-to-equity increased by 9.5% year-over-year, from 0× to 0.1×.
- What is the long-term trend for Cytek Biosciences, Inc.'s debt-to-equity?
- Over 4 years (2021 to 2025), Cytek Biosciences, Inc.'s debt-to-equity has grown at a 8.0% compound annual growth rate (CAGR), from 0× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Cytek Biosciences, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude